浙江越甲药业

Yuejia Pharmaceutical is a clinical-stage biopharmaceutical company based in Shaoxing, China, specializing in the discovery and development of innovative small molecule oncology therapeutics. The company's lead candidate, YJ001, is a highly selective CDK4/6 inhibitor designed to treat advanced solid tumors, with a primary focus on hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Yuejia Pharmaceutical aims to address unmet medical needs in the cancer field by optimizing the safety and efficacy profiles of established therapeutic classes. The company maintains integrated capabilities spanning drug design, preclinical evaluation, and clinical development.